MedTrace Logo

A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

NCT06343636 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2025-02-07

No results posted yet for this study

Summary

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927.

Conditions

  • Healthy
  • Alzheimer Disease

Interventions

DRUG

VG-3927

Dose Escalation

DRUG

Placebo

Dose Escalation

DRUG

VG-3927

One Dose Level

Sponsors & Collaborators

  • Vigil Neuroscience, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-22
Primary Completion
2025-01-10
Completion
2025-01-10
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06343636 on ClinicalTrials.gov